< Back to previous page
Organisation
Van Den Bosch Lab
Research Group
Main organisation:VIB-KU Leuven Center for Brain & Disease Research
Lifecycle:1 Jan 2017 → Today
Organisation profile:Researching the mechanisms of acute and chronic axonal and neuronal degeneration and regeneration, aiming to contribute to the development of new therapeutic strategies for neurodegenerative disorders, studying motor neuron diseases (amyotrophic lateral sclerosis (ALS) and hereditary motor neuropathies), frontotemporal dementia (FTD) and stroke.
Keywords:Neurobiology, neurodevelopment, neurodegeneration, Alzheimer, Parkinson, ALS
Disciplines:Bioinformatics and computational biology, Molecular and cell biology, Neurosciences
Current researchers
1 - 10 of 36 results
- Ludo Van Den Bosch (Responsible)
- Geethika Arekatla (Member)
- Jimmy Beckers (Member)
- Valérie Bercier (Member)
- Thibaut Burg (Member)
- Matilde Contardo (Member)
- Barbosa Correia Adriana Margarida (Member)
- Lenja De Cock (Member)
- Mathias De Decker (Member)
- Joke De Vocht (Member)
Projects
1 - 10 of 14
- Understanding the relation between different disease mechanisms leading to motor neuron dysfunction in ALSFrom16 Jan 2024 → 16 Jan 2024Funding: Other international institutions, not mentioned elsewhere
- VIB Grant for Van Den Bosch Lab_Period:2022-01-01-2026-12-31From1 Jan 2022 → TodayFunding: FRI - Project driven research
- International PhD Programme for Medical DoctorsFrom1 Jan 2022 → TodayFunding: Other EU initiatives out of framework
- The role of lysosomal dysfunction in frontotemporal dementia caused by progranulin mutations (REFOLD-FTD)From1 Jan 2021 → 31 Dec 2022Funding: Private funding of national origin - undefined
- Excellence Hub on Phase Transitions in Aging and Age-Related DisordersFrom1 Jan 2021 → 31 Dec 2023Funding: Other EU initiatives out of framework
- Identification of therapies targeting lipid metabolism & myelination for Charcot-Marie-Tooth disease type 1A using patient derived Schwann cellsFrom2 Oct 2020 → 1 Oct 2023Funding: Other international institutions, not mentioned elsewhere
- Identification of therapies targeting lipid metabolism & myelination for Charcot-Marie-Tooth disease type 1A using patient derived Schwann cells (CMT-LIPID)From1 Jan 2020 → 31 Dec 2020Funding: Other international institutions, not mentioned elsewhere
- Investigating the therapeutic potential of HDACs in a FUS mouse model of amyotrophic lateral sclerosis (HDACALS)From15 Oct 2019 → 14 Oct 2022Funding: Other international institutions, not mentioned elsewhere
- Defining and modulating the stress granule proteome as a therapeutic strategy in Amyotrophic Lateral SclerosisFrom1 May 2019 → 30 Apr 2021Funding: HORIZON.1.2 - Marie Skłodowska-Curie-actions (MSCA)
- Identification, characterization and validation of modifiers or repeat RNA toxicity in C9orf72 amyotrophic lateral sclerosis (ALS)From1 Sep 2018 → 31 Dec 2022Funding: Other international institutions, not mentioned elsewhere
Publications
1 - 10 of 280
- No supportive evidence for TIA1 gene mutations in a European cohort of ALS-FTD spectrum patients(2018)
Authors: Yalda Baradaran, Hung Nguyen Phuoc, Sara Van Mossevelde, Philip Van Damme, Christine Van Broeckhoven, Julie van der Zee
Pages: 293 e9-293 e11 - The sense of antisense therapies in ALS.(2024)
Authors: Sien Van Daele, Pegah Masrori, Philip Van Damme, Ludo Van Den Bosch
Pages: 252-262 - Pyroptosis in Alzheimer's disease: cell type-specific activation in microglia, astrocytes and neurons.(2023)
Authors: Sebastiaan Moonen, Marta Koper, Evelien Van Schoor, Bart De Strooper
Pages: 175-195 - Multiancestry genome-wide association study of 520,000 subjects identifies 32 loci associated with stroke and stroke subtypes(2018)
Authors: Robin Lemmens
Pages: 524-537 - Safety, tolerability, pharmacokinetics, pharmacodynamics, and exploratory efficacy of the novel enzyme replacement therapy avalglucosidase alfa (neoGAA) in treatment-naive and alglucosidase alfa-treated patients with late-onset Pompe disease: A phase 1, open-label, multicenter, multinational, ascending dose study(2019)
Authors: Philip Van Damme
Pages: 167-186 - Individualized risk prediction of major bleeding in secondary stroke prevention: Are we there yet?(2017)
Authors: Robin Lemmens
Pages: 882-883 - PP2A and GSK3 act as modifiers of FUS-ALS by modulating mitochondrial transport.(2024)
Authors: Paraskevi Tziortzouda, Katarina Stoklund Dittlau, Adriana Correia, Thibaut Burg, Philip Van Damme, Thomas Moens, Ludo Van Den Bosch
Pages: 41 - Big Data Approaches to Phenotyping Acute Ischemic Stroke Using Automated Lesion Segmentation of Multi-Center Magnetic Resonance Imaging Data.(2019)
Authors: Robin Lemmens
Pages: 1734-1741 - Restoration of histone acetylation ameliorates disease and metabolic abnormalities in a FUS mouse model.(2019)
Authors: Elisabeth Rossaert, Eveliina Pollari, Lawrence Van Helleputte, Philip Van Damme, Matthieu Moisse, Ludo Van Den Bosch
Pages: 107 - The importance of offering early genetic testing in everyone with amyotrophic lateral sclerosis.(2022)
Authors: Philip Van Damme
Pages: 1207-1210